市場調查報告書
商品編碼
1541335
2024-2032 年自然殺手細胞治療市場報告(按治療方法、應用、最終用戶和地區)Natural Killer Cells Therapeutics Market Report by Therapeutics, Application, End User, and Region 2024-2032 |
IMARC Group年,全球自然殺手細胞治療市場規模達28億美元。罹患癌症的風險不斷上升,加上老年人口不斷增加,正在推動市場發展。
主要市場促進因素:由於缺乏體力活動、不健康的飲食模式以及空氣污染水平日益嚴重,患有癌症、傳染病和肝臟疾病的人數不斷增加,正在推動市場發展。
主要市場趨勢:對臨床研究的廣泛投資,重點關注腫瘤靶向抗體策略,以盡量減少風險和毒性,這是推動市場發展的新興趨勢之一。
競爭格局:全球市場上一些知名的公司包括 Affimed GmbH、Bristol-Myers Squibb Company、Fate Therapeutics、Fortress Biotech Inc.、Glycostem Therapeutics、Innate Pharma SA、Kuur Therapeutics Inc. (Athenex Inc.)、Nkarta Inc.。武田製藥股份有限公司及Ziopharm Oncology Inc. 等。
地理趨勢:由於該地區政府機構為癌症患者制定了眾多財務計劃,北美在市場上表現出明顯的主導地位。
挑戰與機會:阻礙市場的挑戰之一是製造流程的困難。這可以透過改進可擴展的生產方法來克服,以確保品質和功效。
聯合療法越來越受歡迎
將 NK 細胞療法與其他治療方式結合以增強治療效果正在廣泛關注。例如,Innate Pharma 的 Lumoxiti 是一種抗 CD22 免疫毒素,與 NK 細胞結合使用,可破壞和靶向毛細胞白血病中表達 CD22 的癌細胞。此外,這種方法利用了兩種療法的優勢。除此之外,2024年5月,Coeptis Therapeutics Holdings, Inc.(一家為自體免疫、癌症和傳染病開發創新細胞治療平台的生物製藥公司)推出了針對多種抗原的 SNAP-CAR NK 細胞。
監管機構的批准不斷增加
政府機構日益關注提高 NK 細胞生產的可靠性和效率,這是一個重要的生長誘導因素。此外,他們鼓勵將實驗室研究轉化為可行的臨床療法,這將在可預見的未來繼續推動市場發展。例如,2024年4月,下一代NK細胞療法的領先創新者Ingenium Therapeutics獲得美國食品藥物管理局(FDA)授予的治療急性髓性白血病(AML)的孤兒藥資格。
即時監控的需求不斷成長
即時監測和資料分析廣泛整合到 NK 細胞療法開發中,正在提高治療精度和患者治療效果。此外,Bio-Techne 的 Ella 系統等平台可精確監測 NK 細胞擴增過程中細胞激素的產生,確保最佳的細胞功能。即時分析還允許研究人員動態調整培養條件,這有助於提高所產生的 NK 細胞的品質和有效性。這對市場產生正面影響。
The global natural killer cells therapeutics market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.3 Billion by 2032, exhibiting a growth rate (CAGR) of 12.3% during 2024-2032. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.
Major Market Drivers: The growing number of individuals with cancer, infectious diseases, and liver disorders, on account of the lack of physical activities, unhealthy dietary patterns, and the increasing air pollution levels, is catalyzing the market.
Key Market Trends: Extensive investments in clinical studies that focus on tumor-targeted antibody strategies to minimize risks and toxicities are among the emerging trends fueling the market.
Competitive Landscape: Some of the prominent companies in the global market include Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, and Ziopharm Oncology Inc., among many others.
Geographical Trends: North America exhibits a clear dominance in the market, owing to numerous financial schemes by government agencies across the region for cancer patients.
Challenges and Opportunities: One of the challenges hindering the market is the difficulty in manufacturing processes. This can be overcome by improving scalable production methods to ensure quality and efficacy.
Increasing Popularity of Combination Therapies
Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
Growing Regulatory Approval
The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
Rising Demand for Real-Time Monitoring
The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.
IMARC Group provides an analysis of the key trends in each segment of the market, along with the natural killer cells therapeutics market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapeutics, application, and end user.
NK Cell Therapies
NK Cell Directed Antibodies
Currently, NK cell directed antibodies hold the majority of the total market share
The report has provided a detailed breakup and analysis of the market based on the therapeutics. This includes NK cell therapies and NK cell directed antibodies. According to the report, NK cell directed antibodies represented the largest market segmentation.
NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.
Cancer
Gastrointestinal Diseases
Immunoproliferative Disorders
Others
Cancer currently exhibits a clear dominance in the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer, gastrointestinal diseases, immunoproliferative disorders, and others. According to the report, cancer represented the largest market segmentation.
The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.
Hospitals
Research Centers and Institutes
Others
Currently, research centers and institutes hold the majority of the total market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, research centers and institutes, and others. According to the report, research centers and institutes represented the largest market segmentation.
Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.
Affimed GmbH
Bristol-Myers Squibb Company
Fate Therapeutics
Fortress Biotech Inc.
Glycostem Therapeutics
Innate Pharma S.A.
Kuur Therapeutics Inc. (Athenex Inc.)
Nkarta Inc.
Takeda Pharmaceutical Company Limited
Ziopharm Oncology Inc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
April 2024: Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
January 2024: Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapeutics for the treatment of cancer, announced the treatment of the first patients in its Phase 1 trial in multiple myeloma and non-Hodgkin's lymphoma.